Skip to content
PEGS Boston Summit 2023

Event Information:


Date: May 15 to 19, 2023


Boston, MA, United States

Related Models & Services

Immuno-oncology Models
Preclinical Services

PEGS Boston Summit 2023

The PEGS “Protein Engineering & Cell Therapy Summit” Boston Summit is an annual conference focused on protein and antibody engineering, held in Boston, Massachusetts, USA.

The topics covered at the PEGS Boston Summit include antibody engineering, protein expression and purification, cell and gene therapy, protein-protein interactions, oncology studies, immunotherapies, analytical techniques, and clinical case studies.

The conference provides the opportunity to participate in industry-leading talks, interactive sessions, knowledge sharing, and networking with other professionals.

PEGS also offers hands-on workshops on specific topics, poster sessions and exhibits of innovative products and services in the industry. On this occasion, Kiave-Yune Ho Wang Yin, our Director of Innovation and Business Development, will present our poster showcasing our research on immuno-oncology therapy.

Attendees will learn about the latest developments, technologies, and trends in the protein, antibody, and vaccine industries as well as best practices and strategies to accelerate the development and commercialization of new drugs. They will also have the opportunity to meet like-minded colleagues and thought leaders in the field.

Kiave Ho Wang Yin, PhD, Director of Innovation and Business DevelopmentPresenting a poster and attending for TransCure bioServices:

Kiave-Yune Ho Wang Yin, PhD, Director of Innovation and Business Development

Kiave Ho Wang Yin holds a PhD in Immunology/Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She has published more than 10 papers in peer-reviewed international journals in oncology and inflammation. She is a highly experienced scientist in R&D research and in vivo pharmacology preclinical mouse models and joined the TransCure bioservices in 2016.

This event has concluded